Published in Nat Rev Drug Discov on June 01, 2005
Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem (2008) 3.08
Drug-induced autoimmune-like hepatitis. Dig Dis Sci (2011) 2.86
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet (2010) 2.68
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol (2007) 2.30
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol (2012) 1.74
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60
c-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab protein expression in mice. J Biol Chem (2011) 1.57
Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting. Proc Natl Acad Sci U S A (2016) 1.53
Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology (2010) 1.51
Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem (2009) 1.50
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol (2009) 1.49
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother (2007) 1.47
The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett (2009) 1.42
Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance. Proc Natl Acad Sci U S A (2009) 1.32
Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1. J Biol Chem (2010) 1.20
Redox regulation of tumor necrosis factor signaling. Antioxid Redox Signal (2009) 1.18
Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one? J Pharmacol Exp Ther (2009) 1.14
Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev (2009) 1.12
Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel. Toxicol Sci (2009) 1.11
In vitro platforms for evaluating liver toxicity. Exp Biol Med (Maywood) (2014) 1.11
Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother (2011) 1.07
Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci (2013) 1.07
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol (2011) 1.06
Organ-on-a-chip platforms for studying drug delivery systems. J Control Release (2014) 1.06
Drug-induced liver injury: present and future. Clin Mol Hepatol (2012) 1.06
Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci (2010) 1.06
Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol (2011) 1.04
Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol Biosyst (2010) 1.04
Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol (2014) 1.04
Drug-induced acute liver failure. Clin Liver Dis (2013) 1.03
Toxicogenetics: population-based testing of drug and chemical safety in mouse models. Pharmacogenomics (2010) 1.02
Acetaminophen-induced Liver Injury: from Animal Models to Humans. J Clin Transl Hepatol (2014) 1.01
An Update on Drug-induced Liver Injury. J Clin Exp Hepatol (2012) 1.01
Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol Interv (2010) 1.00
Protective role of c-Jun N-terminal kinase 2 in acetaminophen-induced liver injury. Biochem Biophys Res Commun (2008) 1.00
Testing for drug hypersensitivity syndromes. Clin Biochem Rev (2013) 1.00
Interaction of occupational and personal risk factors in workforce health and safety. Am J Public Health (2011) 0.99
Mechanisms of drug-induced liver injury. Clin Liver Dis (2013) 0.99
Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol (2013) 0.98
Liver injury induced by high-dose methylprednisolone therapy: a case report and brief review of the literature. Hepat Mon (2011) 0.97
Selective voting in convex-hull ensembles improves classification accuracy. Artif Intell Med (2011) 0.95
Micropatterned cell-cell interactions enable functional encapsulation of primary hepatocytes in hydrogel microtissues. Tissue Eng Part A (2014) 0.95
Factors affecting drug-induced liver injury: antithyroid drugs as instances. Clin Mol Hepatol (2014) 0.92
Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow. Lab Chip (2015) 0.92
ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective. BMC Neurol (2009) 0.92
Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury. J Pharmacol Exp Ther (2009) 0.92
Molecular mechanisms underlying chemical liver injury. Expert Rev Mol Med (2012) 0.91
Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol (2007) 0.90
The Nuremberg Code subverts human health and safety by requiring animal modeling. BMC Med Ethics (2012) 0.89
The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol (2010) 0.89
High-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markers. PLoS One (2014) 0.88
Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis (2012) 0.88
Acetaminophen-induced acute liver injury in HCV transgenic mice. Toxicol Appl Pharmacol (2012) 0.88
Direct reprogramming of human fibroblasts to hepatocyte-like cells by synthetic modified mRNAs. PLoS One (2014) 0.88
Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. Drug Metab Pharmacokinet (2010) 0.88
Long-term culture and expansion of primary human hepatocytes. Nat Biotechnol (2015) 0.87
Normal atmospheric oxygen tension and the use of antioxidants improve hepatocyte spheroid viability and function. J Cell Physiol (2011) 0.87
Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport. Toxicol In Vitro (2009) 0.87
Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies. J Hum Genet (2015) 0.85
Evaluation of an in vitro toxicogenetic mouse model for hepatotoxicity. Toxicol Appl Pharmacol (2010) 0.85
A multipathway phosphoproteomic signaling network model of idiosyncratic drug- and inflammatory cytokine-induced toxicity in human hepatocytes. Conf Proc IEEE Eng Med Biol Soc (2009) 0.85
Selecting a single model or combining multiple models for microarray-based classifier development?--a comparative analysis based on large and diverse datasets generated from the MAQC-II project. BMC Bioinformatics (2011) 0.84
Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One (2013) 0.84
Discernment of possible mechanisms of hepatotoxicity via biological processes over-represented by co-expressed genes. BMC Genomics (2009) 0.83
Biological therapies: concepts and challenges. Wien Klin Wochenschr (2006) 0.83
Activation of the Nrf2 response by intrinsic hepatotoxic drugs correlates with suppression of NF-κB activation and sensitizes toward TNFα-induced cytotoxicity. Arch Toxicol (2015) 0.82
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol (2014) 0.82
Practical application of toxicogenomics for profiling toxicant-induced biological perturbations. Int J Mol Sci (2010) 0.82
An overview on the proposed mechanisms of antithyroid drugs-induced liver injury. Adv Pharm Bull (2015) 0.81
HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease. Stem Cell Res Ther (2013) 0.81
Effects of an Agaricus blazei aqueous extract pretreatment on paracetamol-induced brain and liver injury in rats. Biomed Res Int (2013) 0.81
Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries. J Cheminform (2015) 0.81
Evidence for immunological (allergic) mechanisms in a subgroup of patients with phenprocoumon-induced liver disease. Eur J Clin Pharmacol (2009) 0.81
Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicol Appl Pharmacol (2007) 0.81
Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies. Technology (Singap World Sci) (2015) 0.81
The adaptive response (drug tolerance) helps to prevent drug-induced liver injury. Gastroenterol Hepatol (N Y) (2012) 0.81
Deficiency of interleukin-15 enhances susceptibility to acetaminophen-induced liver injury in mice. PLoS One (2012) 0.81
Toxicogenomic biomarkers for liver toxicity. J Toxicol Pathol (2009) 0.80
Neutrophil-cytokine interactions in a rat model of sulindac-induced idiosyncratic liver injury. Toxicology (2011) 0.80
Co-culture of Hepatocytes and Kupffer Cells as an In Vitro Model of Inflammation and Drug-Induced Hepatotoxicity. J Pharm Sci (2016) 0.80
Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology. Chem Res Toxicol (2016) 0.80
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. Int J Mol Sci (2016) 0.79
Pregnane X receptor and drug-induced liver injury. Expert Opin Drug Metab Toxicol (2014) 0.79
Identification of a metabolic biomarker panel in rats for prediction of acute and idiosyncratic hepatotoxicity. Comput Struct Biotechnol J (2014) 0.79
The role of transporters in toxicity and disease. Drug Metab Dispos (2014) 0.79
Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. Liver Int (2016) 0.79
Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes. Chem Res Toxicol (2012) 0.79
Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury. Biomed Res Int (2016) 0.78
Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells. Cell Biol Toxicol (2015) 0.78
Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone? Indian J Endocrinol Metab (2014) 0.78
Nationwide longitudinal analysis of acute liver failure in taiwan. Medicine (Baltimore) (2014) 0.78
Baicalin Attenuates IL-17-Mediated Acetaminophen-Induced Liver Injury in a Mouse Model. PLoS One (2016) 0.78
A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury. Sci Rep (2016) 0.77
A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Arch Toxicol (2016) 0.77
3,5,5-trimethyl-hexanoyl-ferrocene diet protects mice from moderate transient acetaminophen-induced hepatotoxicity. Toxicol Sci (2011) 0.77
Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury. CPT Pharmacometrics Syst Pharmacol (2016) 0.77
MicroRNAs in Drug-induced Liver Injury. J Clin Transl Hepatol (2014) 0.77